natgillin/translations-raw huggingface dataset:
A compound for use of claim 6 wherein the disease is selected from rheumathoid arthritis, lupus nephritis, systemic lupus erythematosus. 
Spoj za uporabu prema zahtjevu 6, naznačen time da je bolest odabrana od reumatoidnog artritisa, lupusnog nefritisa, sistemskog eritemskog lupusa.
A kit consisting of separate packs of: 
Komplet (kit), naznačen time da sadrži odvojena pakiranja:
A pharmaceutical composition according to claim 14 which additionally contains at least one further immunomodulating agent. 
Farmaceutski pripravak prema zahtjevu 14, naznačen time da dodatno sadrži barem jedno dodatno imunomodulacijsko sredstvo.
A packaging material (1, 11) for a pharmaceutical product having a coloured element (2, 12) which at about 38°C discolours partially, revealing a marking (2, 12'), wherein: 
Pakirni materijal (1, 11) za farmaceutski proizvod, naznačen time, da ima obojani element (2, 12) koji djelomično gubi boju na temperaturi od oko 38°C, otkrivajući time oznaku (2, 12'), pri čemu:
said coloured element (2, 12) is formed by a first portion, which forms said marking (2', 12') printed with a conventional ink, and by a second portion (2", 12") printed with a thermochromic ink; 
navedeni obojani element (2, 12) se formira pomoću prvog odsječka koji oblikuje navedenu oznaku (2', 12') tiskanu s uobičajenom tintom, i pomoću drugog odsječka (2'', 12'') koji je tiskan termokromnom tintom;
said thermochromic ink is coloured below about 38°C and becomes colourless when said temperature is reached or exceeded; 
navedena termokromna tinta je obojana ispod temperature od oko 38°C i postaje bezbojna kada se dosegne navedena temperatura ili kada se ona prijeđe;
said first portion (2', 12') and second portion (2", 12") are arranged so that said first portion (2', 12') is invisible below about 38°C, but becomes visible when said temperature is reached or exceeded; and 
navedeni prvi odsječak (2', 12') i drugi odsječak (2'', 12'') su raspoređeni tako, da je navedeni prvi odsječak (2', 12') nevidljiv ispod temperature od oko 38°C, ali postaje vidljiv kada se dosegne navedena temperatura ili kada se ona prijeđe; i
said packaging material (1, 11) is a box (1) or a paper present in the packaging of a pharmaceutical product 
navedeni pakirni materijal (1, 11) je kutija (1) ili je papir prisutan u pakiranju za farmaceutski proizvod;
The packaging material (1, 11) according to the preceding Claim 1, wherein the thermochromic ink is of the reversible type. 
Pakirni materijal (1, 11) prema prethodnom zahtjevu 1, naznačen time, da termokromna tinta je reverzibilna.
The packaging material (11) according to claim 1 or claim 2, wherein said pharmaceutical product is an antipyretic drug. 
Pakirni materijal (11) prema zahtjevu 1 ili zahtjevu 2, naznačen time, da navedeni farmaceutski proizvod je antipiretički lijek.
The packaging material (11) according to any one of the preceding Claims, wherein said coloured element (2, 12) is arranged on a surface of an opening/closing flap (3) of the packaging material (1). 
Pakirni materijal (11) prema bilo kojem od prethodnih zahtjeva, naznačen time, da je navedeni obojani element (2, 12) raspoređen na površini zaklopca za otvaranje/zatvaranje (3) pakirnog materijala (1).
The packaging material (11) according any one of the preceding Claims, wherein said coloured element (2, 12) is configured for being pressed by a thumb of a user. 
Pakirni materijal (11) prema bilo kojem od prethodnih zahtjeva, naznačen time, da je navedeni obojani element (2, 12) oblikovan tako, da se može pritisnuti palcem korisnika.
A method of producing a packaging material (1, 11) for a pharmaceutical product having a coloured element (2, 12) which at about 38°C discolours partially, revealing a marking (2', 12'), the production of said coloured element (2, 12) comprising the following steps: 
Postupak proizvodnje pakirnog materijala (1, 11) za farmaceutski proizvod, naznačen time, da pakirni materijal ima obojeni element (2, 12) koji djelomično gubi boju na temperaturi od oko 38°C, otkrivajući time oznaku (2', 12'), dok izrada navedenog obojanog elementa (2, 12) obuhvaća sljedeće korake:
obtaining a packaging material (1, 11); 
pribavljanje pakirnog materijala (1, 11);
printing said marking (2', 12') thereon using an ink of the conventional type; 
tiskanje navedene oznake (2', 12') na pakiranju uporabom tinte uobičajene vrste;
applying a thermochromic ink, which is coloured below the temperature of about 38°C, but becomes colourless when said temperature is reached, so that said marking (2", 12") is substantially invisible below said temperature, but becomes visible when said temperature is reached or exceeded, 
nanošenje termokromne tinte koja je obojana ispod temperature od oko 38°C, ali postaje bezbojna kada se dosegne navedena temperatura, tako da navedena oznaka (2'', 12'') bude uglavnom nevidljiva ispod navedene temperature, no postaje vidljiva kada se dosegne navedena temperatura ili kada se ona prijeđe;
Machine according to at least one of the previous claims, wherein said machine has a motorization system connected to a toothed wheels system (31) aimed to move said horizontal feeding conveyor belt (16) and said vertical conveyor belt, said conveyor belts having different speeds. 
Stroj prema barem jednom od prethodnih zahtjeva, naznačen time da navedeni stroj ima motorizirani sustav spojen na ozubljeni sustav zupčanika (31) namijenjen za pomicanje navedenog vodoravnog dobavnog transportnog remena (16) i navedenog okomitog transportnog remena, te navedeni transportni remeni imaju različite brzine.
Machine according to at least one of the previous claims, wherein said machine has a protective grille (30) mounted on said frame and positioned vertically and adjacent to the vertical conveyor belt (26). 
Stroj prema barem jednom od prethodnih zahtjeva, naznačen time da navedeni stroj ima zaštitnu rešetku (30) postavljenu na navedeni okvir i smještenu okomito i susjedno okomitom transportnom remenu (26).
Machine according to at least one of the previous claims, wherein said frame comprises two grounded side bars (14), which are placed laterally and below said frame and which are inclined towards the ground in correspondence of said feeding mouth (12). 
Stroj prema barem jednom od prethodnih zahtjeva, naznačen time da navedeni okvir sadrži dvije temeljene bočne šipke (14), koje su postavljene bočno i ispod navedenog okvira i koje su nagnute prema tlu u skladu s navedenim dobavnim otvorom (12).
The system of claim 1 further comprising two or more saddle coils (460) coupled to the confinement chamber (100). 
Sustav prema zahtjevu 1, naznačen time, da dodatno obuhvaća dvije ili više sedlastih zavojnica (460) spojenih na priključnu komoru (100).
The system of claim 6 wherein the mirror plug further comprises a set of mirror plug coils wrapped around a constriction (442) in the passageway between each of the first and second formation sections (200) and the first and second divertors (300). 
Sustav prema zahtjevu 6, naznačen time, da zrcalni utikač dodatno obuhvaća komplet zrcalnih zavojnica omotanih oko tjesnaca (442) u prolaznom kanalu između svakog od prvog i drugog tvorbenog dijela (200) i prvog i drugog preusmjerivača (300).
The system of claims 1, 4-5 and 7 wherein the first and second formation sections (200) comprise an elongate quartz tube (210) with a quartz liner. 
Sustav prema zahtjevu 1, 4 do 5 i 7, naznačen time, da prvi i drugi tvorbeni dio (200) obuhvaćaju izduženu kvarcnu cijev (210) s kvarcnom prevlakom.
The system of claims 1, 4-5 and 7 wherein the formation systems are pulsed power formation systems. 
Sustav prema zahtjevu 1, 4 do 5 i 7, naznačen time, da tvorbeni sustavi su pulsirajući strujni tvorbeni sustavi.
The system of claim 10 wherein individual ones of the plurality of power and control units (220) comprising a trigger (222) and control system. 
Sustav prema zahtjevu 10, naznačen time, da pojedinačne jedinice od mnoštva pogonskih i upravljačkih jedinica (220) obuhvaćaju okidač (222) i upravljački sustav.
The system of claims 1, 4-5 and 7 wherein the plurality of neutral atom beam injectors (600) are oriented with an injection path tangential to the FRC with a target trapping zone within separatrix (451) of the FRC. 
Sustav prema zahtjevu 1, 4 do 5 i 7, naznačen time, da je mnoštvo neutralnih injektora atomskih zraka (600) orijentirano s injektorskom putanjom tangencijalno na FRC-konfiguraciju sa zonom ciljnog zahvaćanja unutar separatriksa (451) od FRC-konfiguracije.
is imidazolyl, pyrimidinyl, triazolyl, tetrahydropyranyl, thiazolyl, pyridyl, piperidinyl, phenyl, or oxazolyl; wherein said piperidinyl, pyridyl, imidazolyl, and phenyl are optionally substituted with SO2CH3, C(O)CH3, CH3, CF3, Cl, F, -CN, OCH3, -CF3, or N(CH3)2; and optionally substituted with up to one additional group independently selected from Cl, OCH3, and CH3; and wherein said triazolyl, oxazolyl, and thiazolyl are optionally substituted with one or two CH3 groups; 
je imidazolil, pirimidinil, triazolil, tetrahidropiranil, tiazolil, piridil, piperidinil, fenil, ili oksazolil; pri čemu su navedeni piperidinil, piridil, imidazolil, i fenil proizvoljno supstituirani s SO2CH3, C(O)CH3, CH3, CF3, Cl, F, -CN, OCH3, -CF3, ili N(CH3)2; i proizvoljno supstituirani s do jednom dodatnom skupinom koja je neovisno odabrana iz Cl, OCH3, i CH3; i pri čemu su navedeni triazolil, oksazolil, i tiazolil proizvoljno supstituirani s do jednom ili dvije skupine CH3;
is C(1-2)alkyl, CH2CH2OCH3, or OCH3; or A1 and A2 may be taken together with their attached nitrogen to form a ring selected from the group consisting of: 
je C(1-2)alkil, CH2CH2OCH3, ili OCH3; ili A1 i A2 mogu se uzeti zajedno s njihovim dušikom na koji su spojeni da se dobije prsten koji je odabran iz skupine koja sadrži:
is imidazolyl, triazolyl, thiazolyl, pyridyl, piperidinyl, phenyl, or oxazolyl; wherein said piperidinyl, pyridyl, imidazolyl, and phenyl are optionally substituted with C(O)CH3, CH3, CF3, Cl, F, -CN, OCH3, or N(CH3)2; and optionally substituted with up to one additional group independently selected from Cl, OCH3, and CH3; and wherein said triazolyl, oxazolyl, and thiazolyl are optionally substituted with one or two CH3 groups; 
je imidazolil, triazolil, tiazolil, piridil, piperidinil, fenil, ili oksazolil; pri čemu su navedeni piperidinil, piridil, imidazolil, i fenil proizvoljno supstituirani s C(O)CH3, CH3, CF3, Cl, F, -CN, OCH3, ili N(CH3)2; i proizvoljno supstituirani s do jednom dodatnom skupinom koja je neovisno odabrana od Cl, OCH3, i CH3; i pri čemu su navedeni triazolil, oksazolil, i tiazolil proizvoljno supstituirani s jednom ili dvije skupine CH3;
is C(1-2)alkyl, or OCH3; or A1 and A2 may be taken together with their attached nitrogen to form a ring which is: 
je C(1-2)alkil, ili OCH3; ili A1 i A2 mogu se uzeti zajedno s njihovim dušikom na koji su spojeni da se dobije prsten koji je odabran iz skupine koja sadrži:
A pharmaceutical composition made by mixing a compound of claim 1 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak, naznačen time da se priprema miješanjem spoja prema zahtjevu 1 i farmaceutski prihvatljivog nosača.
A compound of claim 1 for use in treating or ameliorating a RORγt mediated inflammatory syndrome, disorder or disease. 
Spoj prema zahtjevu 1, naznačen time da je za upotrebu za liječenje ili ublažavanje RORγt posredovanog upalnog sindroma, poremećaja ili bolesti.
A cylinder lock, comprising 
Cilindar za bravu koji se sastoji od:
an outer housing part (1) with an outer core (3) rotatable mounted therein, 
vanjskog kućišta (1) unutar kojeg je montirana okretajuća vanjska jezgra (3)
an inner housing part (2) with an inner core (4) rotatable mounted therein, 
unutarnjeg kućišta (2) unutar kojeg je montirana okretajuća unutarnja jezgra (4),
a solid bridge connecting element (6), joining the housing parts (1) and (2), 
čvrsti mostni spojni element (6) koji povezuje kućišta (1) i (2),
the connecting element (6) comprises a central thickened portion (6a) with two lateral arms (6b), 
spojni element (6) sastoji se od središnjeg zadebljanog dijela (6a) sa dvije lateralne ruke (6b),
the central thickened portion (6a) is disposed just below the cam (5), 
središnji zadebljani dio (6a) je postavljen neposredno ispod bregaste osovine (5),
A cylinder lock according to claim 1, characterized in that the connecting element (6) is made of a high-strength steel. 
Cilindar za bravu opisan u zahtjevu 1., čija je posebnost u tome daje spojni element (6) napravljen od čelika visoke čvrstoće.
A Crystalline form ingenol mebutate which is orthorhombic. 
Kristalni oblik ingenol mebutata koji je ortorombičan.
The orthorhombic crystalline ingenol mebutate of claim 1, further characterized by an FTIR-ATR spectrum exhibiting attenuated total reflectance peaks at 3535, 2951, 1712, 1456, 1378, 1246, 1133, 1028 and/or 956 cm-1 with ± 3 cm-1. 
Ortorombični kristalni ingenol mebutat u skladu s patentnim zahtjevom 1, dalje karakteriziran uz pomoć FTIR-ATR spektra koji pokazuje smanjene ukupne reflektivne maksimume na 3535, 2951, 1712, 1456, 1378, 1246, 1133, 1028 i / ili 956 cm-1 sa ± 3 cm-1.
The orthorhombic crystalline ingenol mebutate of claim 1 which is obtainable by crystallization of the compound of formula 1 from acetone, acetonitrile, ethanol, 2-propanol, heptane, methyl tert-butyl ether, monoglyme, toluene, a mixture of acetone and heptane, a mixture of acetone and c-hexane, a mixture of acetone and i-octane, a mixture of acetone and xylene, a mixture of acetonitrile and water, a mixture of ethanol and water, a mixture of 2-propanol and water, a mixture of 2-propanol and heptane, a mixture of 1,4-dioxane and heptane, a mixture of 1,4-dioxane, dimethyl sulfoxide and heptane or a mixture of toluene and heptane. 
Ortorombični kristalni ingenol mebutat u skladu s patentnim zahtjevom 1, koji se može dobiti kristalizacijom spoja formule 1 iz acetona, acetonitrila, etanola, 2-propanola, heptana, metil terc-butil etra, monoglima, toluena, mješavine acetona i heptana, mješavine acetona i c-heksana, mješavine acetona i i-oktana, mješavine acetona i ksilena, mješavine acetonitrila i vode, mješavine etanola i vode, mješavine 2-propanola i vode, mješavine 2- propanola i heptana, mjješavine 1,4-dioksana i heptana, mješavine 1,4-dioksana, dimetil sulfoksida i heptana ili mješavine toluena i heptana.
Mg/m3 The orthorhombic crystalline ingenol mebutate of claim 1 which comprises (a) atoms at atomic positions relative to the origin of the unit cell as set forth in Table 2: 
Ortorombični kristalni ingenol mebutat u skladu s patentnim zahtjevom 1, koji sadrži (a) atome na pozicijama atoma u odnosu na početak elementarne stanice kao što je navedeno u Tabeli 2: Tabela 2:
A pharmaceutical composition as claimed in claim 16 which is suitable for topical administration. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 16 da je pogodan za topikalnu primjenu.
The orthorhombic crystalline ingenol mebutate of claim 1 which is rod shape. 
Ortorombični kristalni ingenol mebutat u skladu patentnim zahtjevom 1, koji je u obliku šipke.
A pharmaceutical composition for topical application to a treatment area of a subject to deliver topically an effective amount of a orthorhombic crystalline ingenol mebutate to treat a skin disorder in the treatment area, said pharmaceutical composition comprising an effective amount of an orthorhombic crystalline ingenol mebutate of claim 1 and a pharmaceutically acceptable vehicle. 
Farmaceutski pripravak za topikalnu aplikaciju na područje liječenja subjekta, za lokalnu primjenu učinkovite količine ortorombičnog kristalnog ingenol mebutata, za liječenje bolesti kože u području liječenja, navedeni farmaceutski pripravak sadrži učinkovitu količinu ortorombičnog kristalnog ingenol mebutata iz patentnog zahtjeva 1 i farmaceutski prihvatljiv nosač.
The pharmaceutical composition of any one of claims 23-30, wherein the skin disorder is actinic keratosis. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 23-30, naznačen time što je bolest kože aktinska keratoza.
A method for purifying an antibody or immunoadhesin from a composition comprising the antibody or immunoadhesin and at least one contaminant, wherein the method comprises either (i) or (ii): 
Postupak pročišćavanja protutijela ili imunoadhezina od sastava koji se sastoji od protutijela ili imunoadhezina i najmanje jednog kontaminanta, naznačen time, da postupak obuhvaća ili (i) ili (ii):
sequential steps of (a) loading the composition onto a cation exchange material at a loading density of greater than about 150 g/L of cation exchange material; and (b) loading a composition recovered from the cation exchange material onto a mixed mode material; or 
uzastopne korake (a) unosa sastava na materijal kationskog izmjenjivača pri gustoći unosa većoj od oko 150 g/L materijala kationskog izmjenjivača; i (b) unosa sastava oporavljenog od materijala kationskog izmjenjivača na materijal mješovitog uzorka; ili
sequential steps of (a) loading the composition onto a mixed mode material; and (b) loading a composition recovered from mixed mode material onto a cation exchange material at a loading density of greater than about 150 g/L of cation exchange material, wherein the cation exchange material is resin particles. 
uzastopne korake (a) unosa sastava na materijal mješovitog uzorka; i (b) unosa sastava oporavljenog od materijala mješovitog uzorka na materijal kationskog izmjenjivača pri gustoći unosa većoj od oko 150 g/L materijala kationskog izmjenjivača, pri čemu se materijal kationskog izmjenjivača sastoji od čestica smole.
The method of claim 4, wherein the monoclonal antibody is an IgG monoclonal antibody. 
Postupak prema patentnom zahtjevu 4, naznačen time, da monoklonsko protutijelo je monoklonsko protutijelo IgG.
The method of claim 10, wherein the antigen binding fragment is selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a scFv, a Fv, and a diabody. 
Postupak prema patentnom zahtjevu 7, naznačen time, da je fragment za vezanje antigena odabran iz skupine koja se sastoji od fragmenta Fab, fragmenta Fab', fragmenta F(ab')2, scFv, Fv i dimernog fragmenta protutijela scFv ili Fv.
The method of claim 16, wherein the density is between about 500 g/L and about 1000 g/L of cation exchange material. 
Postupak prema patentnom zahtjevu 13, naznačen time, da je gustoća unosa od oko 500 g/L do oko 1000 g/L materijala kationskog izmjenjivača.
The method of any one of claims 1-14, wherein the cation exchange material comprises a carboxylic acid functional group or a sulfonic acid functional group. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 14, naznačen time, da se materijal kationskog izmjenjivača sastoji od funkcionalne skupine karboksilne kiseline ili funkcionalne skupine sulfonske kiseline.
The method of any one of claims 1-16, wherein the mixed mode material comprises functional groups capable of anionic exchange and hydrophobic interactions. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 16, naznačen time, da se materijal mješovitog uzorka sastoji od funkcionalnih skupina sposobnih za izmjenu aniona i za hidrofobne interakcije.
The method of claim 25, wherein the conductivity of the equilibration buffer, the wash buffer, and/or the loading buffer is between about 3 mS/cm and 8 mS/cm. 
Postupak prema patentnom zahtjevu 18, naznačen time, da vodljivost pufera za uravnoteživanje, pufera za pranje i/ili pufera za unos, iznosi od oko 3 mS/cm do oko 8 mS/cm.
The method of any one of claims 18-20, wherein the equilibration buffer, the wash buffer, and/or the loading buffer with the cation exchange material and/or the mixed mode material are the same. 
Postupak prema bilo kojem od patentnih zahtjeva 18 do 20, naznačen time, da su pufer za uravnoteživanje, pufer za pranje i/ili pufer za unos s kationskim izmjenjivačem i/ili materijalom mješovitog uzorka, jednaki.
The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof for use in a method of treating, managing or preventing a disease or disorder, wherein the disease or disorder is cancer, a disorder associated with angiogenesis, pain, macular degeneration or a related syndrome, a skin disease, a pulmonary disorder, an asbestos-related disorder, a parasitic disease, dysfunctional sleep or a related disorder, an infectious disease, hemoglobinopathy or a related disorder, or a TNFa related disorder. 
Spoj prema bilo kojem od zahtjeva 1-5, ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer naznačen time da je za uporabu u postupku za liječenje, upravljanje ili sprječavanje bolesti ili poremećaja, pri čemu bolest ili poremećaj je rak, poremećaj povezan s angiogenezom, bol, makularna degeneracija ili srodni sindrom, kožna bolest, plućni poremećaj, poremećaj povezan s azbestom, parazitska bolest, disfunkcionalni san ili srodni poremećaj, zarazna bolest, hemoglobinopatija ili srodni poremećaj, ili poremećaj povezan s TNFa.
the variable heavy chain comprises the variable heavy chain framework sequence from IGHV1-f and the CDRs from the VH chain of murine antibody HP1/2, wherein CDR1 comprises the sequence GFNIKDTYM, CDR2 comprises the sequence RIDPASGDTKYDPKFQV and CDR3 comprises the sequence GMWVSTGYALDF; and, 
varijabilni jaki lanac obuhvaća okvirnu sekvencu varijabilnog jakog lanca od IGHVI-f i CDR-ove od VH-lanca mišjeg protutijela HP1/2, gdje CDR1 obuhvaća sekvencu GFNIKDTYM, CDR2 obuhvaća sekvencu RIDPASGDTKYDPKFQV i CDR3 obuhvaća sekvencu GMWVSTGYALDF; i
the variable light chain comprises the variable light chain framework sequence from geAAH70335.1 and the CDRs from the VL chain of murine antibody HP1/2, wherein CDR1 comprises the sequence KASQSVTNDVA, CDR2 comprises the sequence YASNRYT and CDR3 comprises the sequence QQDYSSPYT, wherein: 
varijabilni slabi lanac obuhvaća okvirnu sekvencu varijabilnog slabog lanca od IGKV4-1 i CDR-ove od VL-lanca mišjeg protutijela HP1/2, gdje CDR1 obuhvaća sekvencu KASQSVTNDVA, CDR2 obuhvaća sekvencu YASNRYT i CDR3 obuhvaća sekvencu QQDYSSPYT, pri čemu su:
amino acid residues at framework positions 24 and 94 of the variable heavy chain according to the Kabat numbering scheme are substituted, wherein the substituted amino acid at framework position 24 is alanine (A) and the substituted amino acid at framework position 94 is aspartic acid (D); 
aminokiselinski ostatci na okvirnim pozicijama 24 i 94 od varijabilnog jakog lanca prema shemi numeriranja Kabat, supstituirani s ne-humanim ostatcima, gdje ne-humani ostatak na okvirnoj poziciji 24 je alanin (A) i ne-humani ostatak na okvirnoj poziciji 94 je aspartna kiselina (D);
The recombinant anti-a4 antibody molecule, or a4-binding fragment thereof, for use according to claim 5, wherein the patient has a cancer. 
Rekombinantna molekula protutijela ili njezin fragment koji veže a4, za uporabu prema zahtjevu 3, naznačena time, da pacijent ima rak.
The recombinant anti-a4 antibody molecule, or a4-binding fragment thereof, for use according to claim 6, wherein the patient has a multiple myeloma or acute myelogeneous leukemia (AML). 
Rekombinantna molekula protutijela ili njezin fragment koji veže a4, za uporabu prema zahtjevu 4, naznačena time, da pacijent ima čvrsti tumor, hematološko maligno stanje, višestruki mijelom ili akutnu mijeloidnu leukemiju (AML).
The recombinant anti-a4 antibody molecule, or a4-binding fragment thereof, for use according to claim 9, wherein the second therapeutic agent is a thrombolytic agent, a chemotherapeutic agent, a neuroprotective agent, an anti-inflammatory agent, a steroid, a cytokine, or a growth factor. 
Rekombinantna molekula protutijela ili njezin fragment koji veže a4, za uporabu prema zahtjevu 3, naznačena time, da liječenje dodatno obuhvaća primjenu na pacijentu nekog drugog terapeutskog sredstva koje je opcijski odabrano od sljedećih: trombolitičko sredstvo, kemoterapeutsko sredstvo, neuroprotektivno sredstvo, protuupalno sredstvo, steroid, citokin ili faktor rasta.
The isolated antibody or protein according to any one of Claims 1 to 7, for use in the treatment of autoimmune disorders and/or inflammatory disorders. 
Izolirano protutijelo prema bilo kojem od zahtjeva 1 do 3, naznačeno time, da se upotrebljava za liječenje autoimunih poremećaja i/ili upalnih poremećaja.